Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience

Safety Related to the Timing of Radiotherapy and Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer: A Single Institutional Experience

Background: The safety impact of radiotherapy (RT) timing relative to immune checkpoint inhibitors (ICIs) for advanced non-small-cell lung cancer (NSCLC) is unclear. We investigated if RT within 14 days (Interval 1) and 90 days (Interval 2) of ICI use is associated with toxicities compared to RT out...

Full description

Bibliographic Details
Main Authors: Michael C. Tjong, Malavan Ragulojan, Ian Poon, Alexander V. Louie, Susanna Y. Cheng, Mark Doherty, Liying Zhang, Yee Ung, Patrick Cheung, Parneet K. Cheema
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Current Oncology
Subjects:
radiotherapy
immunotherapy
timing
safety
toxicity
Online Access:https://www.mdpi.com/1718-7729/29/1/21

Internet

https://www.mdpi.com/1718-7729/29/1/21

Similar Items